In parallel to Cdk inhibitors, which have been extensively under clinical investigations, small molecule inhibitors against cyclin B1 could open up a new door for specific molecular cancer therapy by interfering with its protein stability, binding capacity to Cdk1 or its subcellular localization. This evidence concerns the gene CCNB1 and cancer.